TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01598883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 150 U/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: 150 U/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATryn
Description: 1000 IU

Intervention type: DRUG
Group type: OTHER
Intervention: ATryn
Description: 1000 IU
Study: NCT01846676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Communication Education Program
Description: The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
Study: NCT00523705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets matched to drug
Study: NCT01275612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell infusion
Description: The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
Study: NCT02421731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Description: Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
Study: NCT04671784

Intervention type: OTHER
Intervention: EUS-E
Description: EUS-E
Study: NCT00725348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talarozole
Description: 1.0 mg oral dose per day
Study: NCT01419613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
Study: NCT02904005

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized assessment on depressed patients
Description: At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc).
Study: NCT02850861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condylar reductor
Description: A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
Study: NCT01932320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation A
Description: Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation A
Description: Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation A
Description: Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
Study: NCT03012256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-respiratory management model
Description: Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
Study: NCT03211416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT02345694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Description: Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sub-therapeutic CPAP
Description: Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
Study: NCT04300114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib capsules po. 150 mg twice daily
Study: NCT01932320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation B
Description: Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation B
Description: Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
Study: NCT04300114

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules po. twice daily
Study: NCT01988805

Intervention type: OTHER
Intervention: Blood Draw
Study: NCT01782144

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NutriSystem portion-controlled pre-packaged meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NutriSystem portion-controlled pre-packaged meals
Study: NCT02381249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Study: NCT01932320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation B
Description: Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813: Formulation C
Description: Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
Study: NCT04302701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic treatment using virtual reality
Description: Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
Study: NCT00596154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
Description: The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle.
Study: NCT02818374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral accessibility spatula (SAB)
Study: NCT00960037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Description: Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo equivalent
Description: One capsule daily for 8 weeks
Study: NCT03453762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver
Description: Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonography-guided recruitment maneuver
Description: Recruitment maneuver is guided by ultrasonography.
Study: NCT01581749

Intervention type: RADIATION
Group type: OTHER
Intervention: TrueBeam stereotactic body radiosurgery
Description: 36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
Study: NCT01203436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen Management
Description: Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Management
Description: Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
Study: NCT04684355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time colonoscopic optical diagnosis for colorectal neoplasm
Description: Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
Study: NCT02707510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growing Resiliency And CouragE with Cancer™ (GRACE)
Description: GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
Study: NCT02250365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous, suprasensory ESS
Description: 1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, suprasensory ESS
Description: 1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
Study: NCT01347008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Oral sildenafil citratre, 50mg b.i.d., 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar pill)
Description: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
Study: NCT00459108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study: NCT00874965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrostimulation
Description: 50Hz; 0.4 ms; 30 min; 5 times / week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: 30 min; 5 times / week
Study: NCT01286181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twice daily practice of device-guided slow breathing.
Description: Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
Study: NCT01847417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one
Description: Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two
Description: Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA 100 mg tablet
Description: Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
Study: NCT00832325

Intervention type: BEHAVIORAL
Intervention: interview
Description: The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
Study: NCT03396367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER
Description: The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
Study: NCT01847417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg gastro-resistant tablet
Description: Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
Study: NCT04326140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic-assisted training
Description: The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: robotic-assisted training
Description: The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham mirror therapy
Description: The mirror was masked. The intervention was the same as the mirror therapy.
Study: NCT03307044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Undergo fractional CO2 laser therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00274261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C31G
Description: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.